Multichannel targeted delivery approaches, like the synergistic action of KLA-R16, survivin siRNA, and Herceptin, can help mitigate resistance in recurrent breast cancer driven by CD44 overexpression (26). The gene discussed is BIRC5; the disease is breast carcinoma.